Avalo Therapeutics, Inc.

Advancing abdakibart toward a registrational Phase 3 program in hidradenitis suppurativa, with initiation planned for the first half of 2027 Advancing AVTX-010, a next-generation, long-acting anti-IL-1β antibody, toward an Investigational New Drug submission in the first half of 2027 Cash, cash equivalents and investments of $462.8 million as of September 30, 2026 , expected to fund operations into 2029 WAYNE, Pa., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical-stage biotechnology company focused on developing therapies targeting the IL-1β pathway for immune-mediated inflammatory diseases, today reported financial results for the third quarter of 2026 and provided a business update.

WAYNE, Pa., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated inflammatory diseases, today announced that management will participate in the following investor conferences:

Avalo Therapeutics' positive LOTUS results now support a pivotal trial, and its monthly dosing gives it a potential differentiating factor in HS. Their balance sheet has enough runway to meet their upcoming milestones as well. AVTX-010 offers follow-on potential, but its planned IND submission means that it's still years away from becoming a meaningful value driver for AVTX.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.